Examples of this include the identification of markers for response to methotrexate, the first-line disease-modifying antirheumatic drug (DMARD) to control active inflammation in RA patients,[35] or for the response to biological treatments, such as tumor necrosis factor (TNF) inhibitors, also in RA.[36]. This evidence concerns the gene TNF and rheumatoid arthritis.